SCHEDULE: Oceanpine Slashes LakeShore Biopharma Buyout Offer by 93%

Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. have submitted a revised non-binding proposal to acquire LakeShore Biopharma Co., Ltd, significantly reducing the per-share merger consideration from US$0.90 to US$0.06 due to substantial arbitral awards.

Summary

• Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. (the "Consortium") submitted a Second Revised Proposal to acquire all outstanding ordinary shares of LakeShore Biopharma Co., Ltd not owned by them, Rollover Shareholders, or their affiliates.
• The per-share merger consideration is revised to US$0.06, a significant reduction from the original US$0.90, but still representing a 50% premium to LakeShore Biopharma's last trading price on March 20, 2026.
• The primary reason for the revised offer is the issuance of arbitral awards on January 21 and 22, 2026, by the Kaifeng Arbitration Commission, ordering LakeShore Biopharma's PRC subsidiaries to pay approximately RMB576.5 million in alleged financial liabilities.
• The Consortium has determined these awards constitute a "Company Material Adverse Effect" under the existing Merger Agreement, granting them the right not to consummate the original transaction terms.
• Despite the significant uncertainty, prolonged process, and risks associated with these awards, the Consortium remains committed to proceeding with the acquisition to provide unaffiliated security holders an opportunity to realize value.
• The Revised Transaction will be an all-cash deal for unaffiliated shareholders, funded by rollover equity and cash contributions from Oceanpine Capital Inc. or its affiliates, and is not subject to a financing condition.
• If consummated, the Proposed Revised Transaction would result in the termination of registration for LakeShore Biopharma's Ordinary Shares under Section 12(g)(4) of the Act and delisting from the OTC Pink tier, leading to the company becoming privately held.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development for LakeShore Biopharma shareholders, given the drastic reduction in the buyout offer and the underlying severe financial liabilities.

Positives

• The revised offer of US$0.06 per share still represents a 50% premium to LakeShore Biopharma's last trading price on March 20, 2026.
• The Consortium remains committed to acquiring the company despite significant legal liabilities, offering a potential exit for unaffiliated shareholders.
• The transaction is an all-cash deal for unaffiliated shareholders, providing liquidity.
• The Proposed Revised Transaction is not expected to be subject to a financing condition, reducing execution risk.

Negatives

• The per-share merger consideration has been drastically reduced from US$0.90 to US$0.06, a 93.3% decrease from the original proposal.
• LakeShore Biopharma's PRC subsidiaries face substantial monetary liabilities of approximately RMB576.5 million due to recent arbitral awards.
• The arbitral awards are considered a "Company Material Adverse Effect," indicating severe financial distress for the company.
• The success rate for overturning PRC arbitral awards is low, and the process would be prolonged and uncertain.
• The substantial liabilities could potentially render the company unable to pay its debts as they become due.
• The value for ordinary shares could be further diminished or reduced to nil in the absence of the Revised Transaction.

Risks

• Substantial monetary liabilities of approximately RMB576.5 million from arbitral awards issued by the Kaifeng Arbitration Commission.
• Low success rate for applications to set aside or refuse enforcement of arbitral awards by a competent court in the PRC.
• Potential for LakeShore Biopharma to be unable to pay its debts as they become due and payable.
• Significant uncertainty and a prolonged process of litigation and court proceedings required to overturn the awards.
• Risk of further diminution or reduction to nil of shareholder value in the absence of the Revised Transaction.
• The Second Revised Proposal is non-binding, and there is no assurance that any definitive agreement or transaction will be entered into or consummated.

Future Outlook

The Proposed Revised Transaction, if consummated, would result in the termination of registration for LakeShore Biopharma's Ordinary Shares under Section 12(g)(4) of the Act and delisting from the OTC Pink tier. The company would become a privately held entity, and its board of directors would likely consist of persons designated by the Consortium.

Management Comments

• "We have determined that the arbitral awards... have resulted in a Company Material Adverse Effect... and that, pursuant to Section 8.2(c) of the Merger Agreement, Parent and Merger Sub have the right not to consummate the Merger on the existing terms of the Original Transaction."
• "Notwithstanding the foregoing, we remain willing to proceed with the acquisition of the Company and hereby submit our revised proposal..."
• "We remain committed to assuming such risks and proceeding with the Revised Transaction in order to provide the unaffiliated security holders... with an opportunity to realize value for their Ordinary Shares, which value could otherwise be further diminished or reduced to nil in the absence of the Revised Transaction."
• "We are committed to working with the Special Committee and its advisors to finalize such amendments in an expeditious manner and on terms satisfactory to all parties."
• "This letter constitutes only a preliminary indication of our interest and does not constitute any binding commitment with respect to the transactions proposed in this letter or any other transaction..."

Industry Context

StockSavvy.ai notes that this situation highlights the significant risks associated with M&A activities involving companies with substantial operations in jurisdictions like the PRC, where legal and arbitral outcomes can introduce unforeseen liabilities and materially impact deal valuations. The drastic reduction in offer price underscores the importance of thorough due diligence and robust material adverse effect clauses in cross-border transactions, especially in the biopharma sector which often involves complex regulatory and legal landscapes.

Corporate Governance

Legal Proceedings

• Arbitral awards issued by the Kaifeng Arbitration Commission on January 21, 2026, and January 22, 2026.
• These awards ordered certain PRC subsidiaries of LakeShore Biopharma Co., Ltd to pay a total amount of approximately RMB576.5 million in respect of alleged financial liabilities.
• The Consortium considers these awards to constitute a "Company Material Adverse Effect" as defined in the Merger Agreement.
• Overturning these awards and obtaining a judgment in favor of the Company would require several rounds of litigation and court proceedings, with significant uncertainty and a considerable amount of time to complete.

Stakeholder Impact

• **Unaffiliated Shareholders**: Face a significantly reduced buyout offer (US$0.06 vs. US$0.90) but are offered an opportunity to realize some value for their shares, which could otherwise be diminished or reduced to nil due to the company's substantial liabilities.
• **Consortium (Oceanpine Skyline Inc., Oceanpine Merger Sub Inc., and their affiliates)**: Will acquire the company at a substantially lower price, assuming the risks associated with the arbitral awards, and will roll over their existing equity.
• **LakeShore Biopharma Co., Ltd**: Faces severe financial distress due to RMB576.5 million in arbitral awards, potentially rendering it unable to pay debts. The revised merger offers a path to privatization and resolution of its current challenges.
• **Employees**: Not explicitly mentioned, but a privatization could lead to changes in management and operational structure.

Next Steps

• Work with the Special Committee and its advisors to finalize amendments to transaction documents, Schedule 13E-3, and Proxy Statement.
• Execution and delivery of definitive documentation by all appropriate parties to create a binding commitment for the Revised Transaction.
• If consummated, termination of registration for Ordinary Shares under Section 12(g)(4) of the Act.
• If consummated, delisting from the OTC Pink tier of the OTC Markets.
• Potential changes to the board of directors of the Issuer (as the surviving company in the merger) to consist of persons designated by the Consortium.
• Potential changes in the Issuer's memorandum and articles of association to reflect that the Issuer would become a privately held company.

Key Dates

Recommendation

The drastic 93.3% reduction in the buyout offer from US$0.90 to US$0.06, driven by substantial and difficult-to-overturn arbitral awards of RMB576.5 million, signals severe financial distress and a significant impairment of shareholder value. While the revised offer provides a 50% premium to the last trading price, it is a fraction of the original proposed value. The high uncertainty and prolonged nature of legal challenges in the PRC, coupled with the risk of the company being unable to pay its debts, make the current offer a distressed exit. Investors should consider selling to avoid further potential losses, as the alternative could be a complete loss of value.

Keywords

LakeShore Biopharma, Oceanpine Skyline, Oceanpine Merger Sub, Merger Proposal Revision, Buyout Offer, Arbitral Awards, RMB576.5 million, Material Adverse Effect, Privatization, Delisting, Schedule 13D, Biopharma, China